Advanced Colorectal Cancer, Colorectal Cancer
Conditions
Brief summary
The EORTC GastroIntestinal Tract Cancer Group and the EORTC HeadQuarters wish to set up a European screening platform for advanced colo-rectal cancer (CRC) patients. The goal of this screening platform is to provide quick access to new drugs to patients by offering a new structure for clinical trials. Currently some of the most challenging clinical questions arise from the molecular sub-division of CRC that would theoretically allow to inhibit the specific, altered pathways in the patients. A major problem for trials in this personalized medicine is that the low frequency of the different mutations requires a high effort for screening and identifying the patients. The EORTC CRC screening platform will hopefully offer a feasible and efficient way to characterize the patients on the molecular basis of their tumors and allow to offer them rapid and preferential participation in clinical studies with new drugs targeted to their specific pathway alterations.
Interventions
GENETICTumour markers testing
Tumour markers testing in patients advanced or metastatic colo-rectal cancer.
Sponsors
European Organisation for Research and Treatment of Cancer - EORTC
Study design
Observational model
CASE_ONLY
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Colo-rectal cancer (advanced or metastatic) * Before patient registration, written informed consent must be given according to ICH/GCP, and national/local regulations.
Exclusion criteria
* Absence of patient's consent
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Tumour markers assessment | Within 1 week after patient registration | Five basic tumour markers will be tested: Kras, nras, braf, MSI and PKI3 |
Countries
Belgium, Cyprus, France, Germany, Greece, Italy, Poland, Portugal, Spain, Sweden, Switzerland
Outcome results
None listed